Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer
C Gamell, T Gulati, B Solomon, S Haupt, Y Haupt
MOLECULAR & CELLULAR ONCOLOGY | TAYLOR & FRANCIS INC | Published : 2017
A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16INK4a (best known as p16), commonly due to promoter hypermethylation. We recently reported a novel regulatory pathway involving E6-associated protein and cell division control protein 6, which provides a methylation-independent mechanism for p16 silencing in patients with a particularly aggressive form of NSCLC.
Related Projects (2)
Awarded by Cancer Council Victoria
Awarded by National Health and Medical Research Council
Awarded by Victoria Cancer Agency-Richard Pratt Foundation
The work in the authors' laboratory is supported by grants from Cancer Council Victoria's Grant-in-Aid Scheme (1085154), National Health and Medical Research Council (NHMRC 1063389) and a fellowship to CG from Victoria Cancer Agency-Richard Pratt Foundation (Pratt14002).